

American Society of Transplant Surgeons

Schedule-at-a-Glance Friday, January 24, 2014

7:00 a.m. – 6:00 p.m.	Registration Open Rotunda East Ballroom, Level 2
7:00 – 8:00 a.m.	Continental Breakfast
	Americana Foyer, Level 2
8:00 – 11:00 a.m.	ASTS Legislative Update and Advocacy Symposium Americana Salon 4, Level 2
11:00 a.m. – 7:30 p.m.	Exhibit & Poster Hall Open
•	Americana Salon 1,2 & 3, Level 2
11:00 a.m. – 12:00 p.m.	Lunch
•	Americana Salon 3, Level 2
12:00 – 3:20 p.m.	ASTS Winter Symposium: Meeting the Challenges of
	Innovation
	Americana Salon 4, Level 2
12:00 – 12:20 p.m.	Welcome & Overview
_	Americana Salon 4, Level 2
12:20 – 12:50 p.m.	David Hume Lecture
•	Americana Salon 4, Level 2
12:50 – 1:50 p.m.	Innovating in the Operating Room: Stories of Innovation
	Americana Salon 4, Level 2
1:50 – 2:00 p.m.	Break
_	Americana Salon 3, Level 2
2:00 – 2:30 p.m.	Innovation Outside the Operating Room
	Americana Salon 4, Level 2
2:30 – 3:00 p.m.	Threats to Innovation
	Americana Salon 4, Level 2
3:00 – 3:20 p.m.	Innovation at the Crossroads
	Americana Salon 4, Level 2



Schedule-at-a-Glance Friday, January 24, 2014

3:30-5:00 p.m.	Poster Session with Presenters in Attendance
3.30 - 3.00 p.m.	I USICI SESSIUII WILII I IESCIILEIS III ALLEHUAIICE

Americana Salon 1, 2, & 3, Level 2

The Top Ten posters will be presented "Poster of Distinction" awards during the Exhibit Hall Reception.

Presenters must be in attendance at their poster in order to be

eligible for an award.

5:15 – 6:30 p.m. Career Development Seminar: Finding Your Niche

Poinciana Salon 1, 2, & 3, Level 2

6:30 – 7:30 p.m. Exhibit Hall Reception with Poster of Distinction

Awards Presentation and Junior Investigator Award

Presentation

Americana Salon 1, 2, & 3, Level 2

Legislative Update and Advocacy Symposium

Americana Salon 4. Level 2

7:00 – 8:00 a.m. Breakfast

Americana Foyer, Level 2

8:00 – 8:10 a.m. Introduction

David J. Reich, MD, FACS

Drexel University College of Medicine, Hahnemann University

William C. Chapman, MD, FACS *Washington University in St. Louis*

8:10 – 8:50 a.m. Keynote Address: Crash Course on Health Care Reform in an

Era of Budgetary Constraint (ACA, SGR, P4P, Liability Reform,

Workforce and Training Issues, Research Funding)

David B. Hoyt, MD, FACS *Executive Director, ACS*

8:50 – 9:05 a.m. Legislative Advocacy Priorities in Transplantation

David J. Reich, MD, FACS

Drexel University College of Medicine, Hahnemann University

9:05 – 9:45 a.m. How and with Whom Do We Move our Agenda through the

Federal Legislature?

Peggy Tighe, JD

Powers, Pyles, Sutter & Verville, PC

9:45 – 10:05 a.m. What to Be Vigilant about on Your Home Front – Transplant

Advocacy at the State Level (Essential Health Benefits, Exchanges,

Medicare/Medicaid Reform)

Peter W. Thomas, JD

Powers, Pyles, Sutter & Verville, PC

10:05 – 10:35 a.m. Government Perspective

Rep. Michael C. Burgess, MD (R-TX)

U.S. House of Representatives

10:35 – 10:55 a.m. **Q&A/Panel Discussion**

David B. Hoyt, MD, FACS

Peter W. Thomas, JD

Peggy Tighe, JD

David J. Reich, MD, FACS

10:55 – 11:00 a.m. Wrap-Up

David J. Reich, MD, FACS

Drexel University College of Medicine, Hahnemann University

William C. Chapman, MD, FACS *Washington University in St. Louis*

ASTS State of the Art Winter Symposium: Meeting the Challenges of Innovation

Americana Salon 4, Level 2

11:00 a.m. – 12:00 p.m. Lunch

Americana Salon 3, Level 2

Meeting the Challenges of Innovation

Moderators:

David C. Mulligan, MD *Yale University* Michael J. Englesbe, MD

University of Michigan

12:00 – 12:05 p.m.

Welcome & MOC Overview

Michael J. Englesbe, MD *University of Michigan*

Matthew H. Levine, MD, PhD *University of Pennsylvania*

12:05 – 12:20 p.m.

Overview: Meeting the Challenges of Innovation

David C. Mulligan, MD

Yale University

12:20 - 12:50 p.m.

David Hume Lecture

Arnold Diethelm, MD

Professor Emeritus

University of Alabama, Birmingham

12:50 - 1:50 p.m.

Innovating in the Operating Room: Stories of Innovation

Lloyd E. Ratner, MD, MPH

Columbia University

Jean C. Emond, MD

Columbia University and the New York Presbyterian Hospital

Clyde F. Barker, MD

University of Pennsylvania

Robert B. Love, MD, FACS

Fraedtert and Medical College of Wisconsin

Linda C. Cendales, MD

Emory University

Andreas Tzakis, MD, PhD

Cleveland Clinic Florida

1:50-2:00 p.m.

Break

Americana Salon 3, Level 2

Innovation Outside the Operating Room

Moderators:

John C. Magee, MD University of Michigan Alexander T. Maskin, MD University of Nebraska

2:00 – 2:10 p.m. **Drug Development**

Thomas C. Pearson, MD, PhD

Emory University

2:10 – 2:20 p.m. Device Development

James V. Guarrera, MD, FACS Columbia University Medical Center

2:20 – 2:30 p.m. Research Development

Robert M. Merion, MD, FACS

University of Michigan Medical Center

Threats to Innovation

Moderators:

John C. Magee, MD University of Michigan Alexander T. Maskin, MD University of Nebraska

2:30 – 2:40 p.m. Financial Threats to Innovation

Michael M. Abecassis, MD, MBA

Northwestern University

2:40 – 2:50 p.m. Regulatory Threats to Innovation

Robert M. Montgomery, MD, PhD

Johns Hopkins University

2:50 – 3:00 p.m. Training Threats to Innovation

Abhinav Humar, MD

Thomas E. Starzl Transplant Institute

3:00 – 3:20 p.m. Innovation at the Crossroads: Panel Discussion

Moderator:

John C. Magee, MD University of Michigan

Panel:

Michael M. Abecassis, MD, MBA

Northwestern University

Robert M. Montgomery, MD, PhD

Johns Hopkins University

Abhinav Humar, MD

Thomas E. Starzl Transplant Institute

Poster Session with Presenters in Attendance

3:30 – 5:00 p.m. The Top Ten posters will be presented "Poster of Distinction"

awards during the Exhibit Hall Reception. Presenters must be in attendance at their poster in order to be eligible for an award.

Career Development Seminar: Finding Your Niche

Poinciana 1, 2, & 3, Level 2

Moderator:

Zoe A. Stewart, MD, PhD

University of Iowa Hospitals and Clinics

5:15 – 6:30 p.m. Jonathan S. Bromberg, MD, PhD

University of Maryland

Daniela P. Ladner, MD

Northwestern University Feinberg School of Medicine

John C. Magee, MD *University of Michigan*

Elizabeth A. Pomfret, MD, PhD

Lahey Clinic

6:30 – 7:30 p.m. Exhibit Hall Reception with Poster of Distinction Award

Presentation and Jr. Investigator Award Presentation

Americana Salon 3, Level 2

POSTER SESSION

** Denotes Junior Investigator Award Recipient

Donor Management

P-1 The Use of Living Donor Kidneys with Small Renal Cell Carcinoma in Transplantation Obi Ekwenna, Miami Transplant Institute

P-2 Improving Donor Conversion Rates at a Level One Trauma Center: Impact of Best Practice Guidelines

Bobby Gibbons II, Orlando Health

P-3 Comparison of Two Hospital Educational Approaches to Increase Live Donor Kidney Transplantation amongst Minorities

Mencia Gomez De Vargas, Montefiore-Einstein Medical Center for Transplantation

P-4 Post Living Kidney Donor Follow up: An Algorithm for Process Improvement Deonna Moore, Vanderbilt University Medical Center

P-5 Tobacco Abuse Does Not Affect Organ Quality in Deceased Donor Renal Transplantation Sunil Patel, University of Buffalo

P-6 Implementation of an Enhanced Recovery Protocol in Living Kidney Donors Seth Waits, University of Michigan

Heart

P-7 Kidney-Induced Cardiac Allograft Tolerance across a Full MHC-Barrier in Miniature Swine Sebastian Michel, Massachusetts General Hospital

Kidney

P-8 Socioeconomic Disparities among Deceased Donors and Kidney Transplant Recipients Joel Adler, Massachusetts General Hospital

P-9 Kidney Transplant Candidate Understanding of High Risk Kidneys Saveeda Ahsanuddin, Montefiore-Einstein Medical Center for Transplantation

P-10 Using Analytic Morphomics to Assess Long Term Risk in Kidney Donors Mitchell Alameddine, University of Michigan

P-11 Influence of Prolonged Cold Ischemia in the Era of Marginal Donor Utilization Yousef Al-Shraideh, Wake Forest University

P-12 Single versus Dual (en bloc) Kidney Transplants from Donors <5 Years of Age: A Single Center Experience

Yousef Al-Shraideh, Wake Forest University

P-13 Improved Outcomes with Transplantation and Surgical Management in Neonatal Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Jennifer Berumen, Stanford University

P-14 Leukopenia Management in Thymoglobulin Treated Renal Transplant Recipients

Lynsey Biondi, Lehigh Valley Health Network

P-15 Innovation in Measuring Transplant Center Performance: Analysis of Patients' Perspectives on Inpatient Care

Apurba Chakrabarti, University of Michigan Medical School

P-16 Mammography for Women 40 to 50 during Pre-Kidney Transplant Evaluation

Devan Cote, Case Western Reserve University School of Medicine

P-17 Racial Differences in the Predominant Factors Associated with Early Graft Loss in Kidney Transplant Recipients

Kevin Douglas, Medical University of South Carolina

P-18 Does High Recipient BMI Influence Outcomes in Deceased Donor Kidney Transplantation? A Paired Donor Kidney Analysis

Umar Farooq, Wake Forest Baptist Health

P-19 Effect of Donor Obesity on Outcomes in Expanded Criteria Donor Kidney Transplantation

Umar Faroog, Wake Forest Baptist Health

P-20 Is Recipient BMI ≥40 a Contraindication to Kidney Transplantation?

Umar Farooq, Wake Forest Baptist Health

P-21 Graft Failure Due to Noncompliance among 628 Kidney Transplant Recipients with Long-term Followup: A Single-Center, Observational Study

Jeffrey Gaynor, University of Miami

P-22 The Impact of the Share 35 Policy on First Allograft Outcomes among Kidney Transplant Recipients**

Meera Gupta, University of Pennsylvania

P-23 Perceived Knowledge of Kidney Transplantation and the Pursuit of a Live Donor

Natasha Gupta, Johns Hopkins University School of Medicine

P-24 Anticoagulation after Renal Transplantation Prevents Graft Thrombosis in Patients with

Thrombophilia

Christine Hwang, University of Texas Southwestern Medical Center

P-25 Highly-Sensitized Kidney Transplant Candidates: Opportunities for Transplant

Colleen Jay, Mayo Clinic Rochester

P-26 Preemptive Kidney Transplantation: The Nation's Report Card

Colleen Jay, Mayo Clinic Rochester

P-27 Single Center Review of Renal Transplant Outcomes in Recipients on Warfarin

Steven Kapeles, University of Michigan Medical School

P-28 Clopidogrel Is Associated with Decreased Survival in Renal Transplant Recipients

Steven Kapeles, University of Michigan Medical School

P-29 Renal Transplantation in Elderly Patients Older than 70 Years: Re-assessing the Risk at a Center

Irene Kim, Cedars-Sinai Medical School

P-30 Does Insurance Type Influence Risk Assessment in Elderly Kidney Candidates?

Rupak Kulkarni, University of Florida

P-31 KDPI Does Not Predict Early Readmission in Kidney Transplant

Cynthia Leaphart, University of Florida College of Medicine

P-32 Impaired Endothelium Dependent Relaxation—a Proxy of Viability for Donation after Circulatory Death (DCD) Kidneys

Gwyn Lee, University of Leicester

P-33 Cyclosporine A Induced Immediate Vasoconstriction Demonstrated During and Impaired Endothelium Dependent Relaxation Demonstrated after Reperfusion in a Porcine Donation after Circulatory Death (DCD) Model

Gwyn Lee, University of Leicester

P-34 Associations of Pre-Transplant Narcotics Use with Death and Graft Loss after Kidney Transplantation Krista Lentine, St. Louis University

P-35 Measuring Utility and Fairness in Kidney Paired Donation (KPD)**

Wenhao Liu, Stanford University

P-36 Long-term Outcomes among HIV-infected Kidney Transplant Recipients

Jayme Locke, University of Alabama

P-38 Patterns of Hospital Admissions Before and After Renal Transplantation: Lessons for New Quality Paradigms

Raymond Lynch, Emory University

P-39 Redefining Readmission in Renal Transplantation -- Variation in Resource Utilization and Outcome Raymond Lynch, Emory University

P-40 Frailty in Kidney Transplant Recipients of All Ages**

Mara McAdams-DeMarco, Johns Hopkins University

P-42 Patterns and Sequelae of Early Hospital Readmission after Kidney Transplantation

Mara McAdams-DeMarco, Johns Hopkins University

P-45 Maximizing Living Donor Transplants through National PKE Programs

Silke Niederhaus, University of Maryland Medical Center

P-46 The Effects of Erratic Peri-operative Blood Pressures and Glucoses on Readmissions in Kidney Transplantation

John Odeghe, Medical University of South Carolina

P-47 Sequelae of Concurrent Antibody- and Cell-Mediated Rejection Following Kidney Transplantation Babak Orandi, Johns Hopkins University

P-48 Virtual Microscopy Improves Sharing of Deceased Donor Kidneys**

Adena Osband, Rutgers University, Robert Wood Johnson Medical School

P-49 Screening Colonoscopy Should Be Required for Kidney Transplant Listing

Paul Park, Western Reserve University School of Medicine

P-50 Hypothermic Pump Perfusion Parameters in the Determination of Reversibility of Deceased Donor Renal Reperfusion Injury

Sunil Patel, University of Buffalo

P-51 Preoperative Screening for Intracranial Aneurysms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Madhukar Patel, Massachusetts General Hospital

P-52 Retroactive Application of the KDRI System to Transplants Performed in ECD/SCD Era: A Single Center Analysis

Rajesh Ramanathan, Virginia Commonwealth University Medical Center

P-53 Outcomes of Kidney Transplant Recipients with Bladder Dysfunction

Dushyanth Srinivasan, University of Michigan

P-54 Increased Graft Loss in Obese Kidney Transplant Patients Is Limited to Older Recipients

Zoe Stewart, University of Iowa Organ Transplant Center

P-55 The Majority of Living Kidney Donor Candidates Fail to Complete a Full Donor Evaluation: The University of Iowa Experience

Zoe Stewart, University of Iowa Organ Transplant Center

P-56 Differences in Patient Survival among Sexagenarian and Septuagenarian Renal Transplant Recipients and Donors: The Context for Older Living Donors

Carrie Thiessen, Yale School of Medicine

P-58 Protocol Based Induction Therapy Improves Rejection Rates, Complications, and Transplant Event Costs in Adult Kidney Transplant Recipients

Christopher Vandivort, Medical University of South Carolina

P-59 Comparative Study of Laparoscopic and Mini-Incision Open Donor Nephrectomy

Kunal Yadav, University of Iowa Hospitals and Clinics

P-60 Outcomes of Kidney Transplantation in HCV Seropositive Recipients: A Mate Analysis

Hillary Yaffe, Montefiore Medical Center Department of Surgery

P-61 Hepatitis B Immunity among Patients Undergoing Kidney Transplant Evaluation

Vanessa Yeh, Case Western Reserve University School of Medicine and University Hospitals Case Medical Center

<u>Liver</u>

P-62 Seasonal Variation in Liver Transplantation

Zachary Abecassis, Northwestern University

P-64 Sorafenib Reduced Recurrence of Large Hepatocellular Carcinoma after Liver Transplantation

Emad Asham, The Methodist Hospital

P-65 Prediction of Futility Following Liver Transplantation: A Blinded, Prospective Comparison of Riskscoring Systems

Elaine Cheng, University of California, Los Angeles

P-66 Failure to Rescue in Pediatric Liver Transplantation: A Potential OI Tool

Shannon Cramm, University of Michigan

P-67 The Bloody Cost of High MELD Liver Transplant

Elika Derek, University of Southern California

P-68 Liver Transplantation Outcomes among Patients with Inborn Errors of Metabolism: Worth the Risk?

Andre Dick, Seattle Children's Hospital

P-69 Intra-Operative Hepatic Arterial Flow Predicts Hepatic Artery Complications after Deceased Donor Liver Transplantation

Hoylan Fernandez, Baylor University Medical Center

P-70 Post-operative Cardiac Events, but Not Severity of Coronary Artery Disease, Is Associated with Worse Survival in Liver Transplant Recipients

Albert Flowers, Methodist University Transplant Institute

P-71 Liver Transplantation for Hepatocellular Carcinoma: the Impact of the Donor Risk Index

Edson Franco, Tampa General Medical Group

P-72 Bariatric Surgical Intervention in the Obese Pre-Liver Transplant Patient: Is it Justifiable?

Sherilyn Gordon Burroughs, Houston Methodist Hospital

P-73 Alterations in Hippo Signaling Pathway during Liver Regeneration

James Grijalva, Boston Children's Hospital

P-74 Reevaluating the Impact of Portal Vein Thrombosis on Liver Transplant Outcomes: A Ten Year Retrospective Analysis

Hishaam Ismael, Henry Ford Hospital

P-75 The Effect of Social Support on Liver Transplant Outcomes

Kristy Kast, University Hospitals Case Medical Center

P-76 Low Disease Recurrence Rates after Liver Transplantation (OLT) for Non-alcoholic Steatohepatitis (NASH)

Norio Kawamura, Cleveland Clinic

P-77 Intraoperative Continuous Veno-Venous Hemofiltration Facilitates Liver Transplantation in Patients with Acute Renal Failure

Patrick Kelly, University of Maryland School of Medicine

P-78 Long Term Incidence and Impact of Biliary Complications after Adult Right Lobe Living Donor Liver Transplantation**

Peter Kim, Baylor University Medical Center

P-79 Hepatic Arterial Flow Predicts Biliary Complications and Survival in Liver Transplantation

Peter Kim, Baylor University Medical Center

P-80 No Ischemic Cholangiopathy Following Liver Transplantation from DCD Donors: Implementation of

Selective Organ Recovery Criteria and TPA Administration before Cold Perfusion**

Emad Kishi, Mount Sinai Medical Center

P-81 Frailty, Trunk Muscle Size, and Pre-Liver Transplant Mortality

Lindsey Kolar, University of Michigan Medical School

P-82 Improving Outcomes in Liver Transplantation from Donation after Circulatory Death

Adam Kressel, Ochsner Clinic Foundation

P-83 Belatacept Is Safe and Effective Bridging Immunosuppression in Liver Transplant Recipients with Renal Dysfunction

John LaMattina, University of Maryland School of Medicine

P-84 Paraspinous Muscle Area and Surgical Outcomes in Liver Transplantation

Christopher Lee, University of Michigan Healthy System

P-85 Long-term Outcomes among HIV-infected Liver Transplant Recipients

Jayme Locke, University of Alabama at Birmingham

P-86 Current Allocation Policy Does Not Account for Increased Risk of Death Following Sudden Rise in MELD

Allan Massie, Johns Hopkins School of Medicine

P-87 Increased Risk of Extended Cold Ischemic Time in Nighttime Procurements

Lisa McElroy, Northwestern University Feinberg School of Medicine

P-88 A Broad Assessment of Outcomes of Adult Liver Retransplantation in the MELD Era: Is It Time to Reconsider Its Indications?

Martin Montenovo, University of Washington

P-89 The Clinical Impact of Hepatitis C-Positive Donors in Liver Transplantation: Patient Protection or Lost Opportunities?

Martin Montenovo, University of Washington

P-90 Long-term Outcomes of Pediatric Liver Retransplantation in the PELD Era

Martin Montenovo, University of Washington

P-91 Fate of the Biliary Tree after Hepatic Artery Lesions in OLT. Is it Time to Challenge the Current UNOS Policy for Re-transplantation?

Martin Montenovo, University of Washington

P-92 Orthotopic Liver Transplantation (OLT) in Septuagenarians: A Single Center Experience

Bhuvana Muthuswamy, The Houston Methodist Hospital

P-93 Leukocyte MMP-9 Mediates Fibrous Capsule Formation Following Hepatic Radiofrequency Ablation in Mice

Trevor Nydam, University of Colorado School of Medicine

P-94 Survival Outcomes in Liver Transplant Recipients with MELD of 40 and Higher—a Decade Long Experience

Hinaben Panchal, Icahn School of Medicine at Mount Sinai

P-95 Donor Administration of Cell Impermeants Rescue DCD Livers

Dan Parrish, Virginia Commonwealth University

P-96 Impact of Hepatic Venous Cross-circulation in Fused Liver Separation

Rajesh Ramanathan, Virginia Commonwealth University Medical Center

P-97 A Matched Pair Analysis of Multicenter Long-term Follow-up after Split Liver Transplantation with Extended Right Grafts

Mitchell Ross, University of Pittsburgh School of Medicine

P-98 Predictors of Graft Nonfunction (GNF) Following Orthotopic Liver Transplantation: A Single-Center Analysis of 1519 Consecutive Transplants

Imtiazuddin Shaik, University of California, Los Angeles

P-99 Reduced Hepatitis B Immunoglobulin (HBIg) Role in the Era of Potent Nucleos(t)ide Analogues for Hepatitis B Virus (HBV) Prophylaxis

George Singer, Rush University Medical Center

P-101 Abdominal Adiposity, Body Composition and Survival after Liver Transplantation

Michael Terjimanian, University of Michigan

P-102 Living Donor Liver Transplant for HCC: A Proposal

Guiliano Testa, Baylor University Medical Center

P-103 Sinusoidal Dilatation after Liver Transplant. A Predictor of HCV Recurrence?

Ioannia Theodoropoulos, Henry Ford Hospital

P-104 Resolution of Acute Kidney Injury after Liver Transplantation: Single Center Experience

Tsuvoshi Todo, Stanford University School of Medicine

P-105 Mortality and Failure to Rescue Following Liver Transplantation

Patrick Underwood, University of Michigan Medical School

P-106 Risk of Recidivism and Long Term Outcome in Recipients of Liver Transplantation with Alcoholic Liver Disease

Jason Vanatta, Methodist University Transplant Institute

P-107 Impact of Preexisting Diabetes Mellitus (DM) on Outcomes after Liver Transplantation in Recipient with NASH

Irum Zaheer, The Methodist Hospital

P-108 A Rapid, Reproducible, Non-invasive Predictor of Liver Graft Utilization

Ali Zarrinpar, University of California, Los Angeles

P-109 A Study on the Safety and Effectiveness of Everolimus in Liver Transplant Recipients for Pancreatic Neuroendocrine Tumors

Xu Zhao, University of Tennessee

Other

P-111 A Retrospective Study of Early Post-Transplant Nosocomial Infections

Peter Dorschner, Northwestern University

P-112 Comparative Analysis of the Donation and Transplant Project with the New Organic Law of Donation and Transplant of Organs, Tissues and Cells in Ecuador

Sergio Enderica-Gonzalez, Universidad San Francisco de Quito

P-113 Graft Outcomes Following Pregnancy in Transplant Recipients

Allison Janda, University of Michigan Medical School

P-114 Increased Frequency of Gut-homing CCR6high CD4+ Memory T Cells in Human Intestinal Transplantation

Hiroto Kayashima, Cleveland Clinic

P-115 Role of Control of Inflammation in Islet Engraftment after Total Pancreatectomy and Islet Transplantation for Chronic Pancreatitis

Peter Kim, Baylor University Medical Center

P-117 The Proteomic Signature of Murine Intestinal Allograft Rejection

Mihai Oltean, Sahlgrenska University Hospital

P-118 Implications of Solid Organ Transplantation on Fertility, Pregnancy Complications, and Prenatal Counseling

Devon Rupley, University of Michigan Medical School

P-119 Mesenchymal Stem Cells Enhance Bone Marrow Engraftment and Induce Immunological Tolerance

Reza Saidi, Brown University

Pancreas

P-120 Mitigation of Racial Disparities in Outcomes after Simultaneous Pancreas and Kidney Transplantation**

Jayme Locke, University of Alabama at Birmingham

P-121 Pancreas Transplant Salvage after Leak: Is it worth it?

Kasi McCune, University of Wisconsin

P-122 Pancreas Transplantation from Donors after Cardiac Death: An Update of the UNOS Database** Eric Siskind, North Shore Long Island Jewish Health System

P-123 Pancreas Transplantation Outcomes Differ Based on Age Groupings: An Analysis of the UNOS Database

Eric Siskind, North Shore Long Island Jewish Health System

P-124 Patients with Prior Pancreas Transplants Fare Worse Following Kidney Allograft Failure

Kenneth Woodside, Case Western Reserve University and University Hospitals